MBHS MBeach Software Inc

[PENNYMASTER]

Put MBHS on watch. The companys latest update was about what stage there SkinScan 650 is at and how physicians can do this test right in there offices. Were going to see some big things from this company in the near future, Stock has been showing some good volume and decent gains these past couple of days. Today hasnt done much but I think its ready for some big news soon!! I think were at a good entry price here @.25 We have seen thisat .38 a few weeks ago and when news hits the wire I think we will be trading at that level again or even higher. I think were at a good entry price here. Here is the latest news from 7/16 there is also a link to the webite in the news. Check it out..



TEL AVIV, Israel, July 16, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update. The Company believes in the importance of regular communication and timely information delivered to investors. To this end, MBHS is committed to share with its stockholders regular updates on its progress.



MBHS, through its wholly owned subsidiary Skin Cancer Scanning ltd. ("SCS") is pioneering the development and commercialization of a revolutionary and proprietary diagnostic device for the early detection and diagnosis of skin cancer. Our product, an advanced stage prototype, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers.



SkinScan 650's state-of-the-art technology will enable physicians to improve their diagnostic abilities using SkinScan 650. This will replace current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and lower chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.



To date, we have successfully conducted two stages of clinical trials. The results from 128 scanned nevi demonstrated 92.4% accuracy in diagnosing non-melanoma skin cancer. These results are significantly higher than the 75% accuracy achieved by an experienced physician and 65% accuracy achieved by a general practitioner.



For more information on SCS, visit the company's new website at Skin Cancer Scanning Ltd. (SCS) :: Symbol (OTCBB): MBHS

[PENNYMASTER]

Here is some long awaited news on MBHS, This company is going to explode in the am.Imo it was a bargin to get in on this one at $0.22- 0.24. I think the news of the company targeting international markets is a great step foward especially in Russia where the early dectection rate is extremley low. This one should be trading back up to $0.33-0.38 or higher. Stock has shown some great volume and some price apprecation. I am including the news for you to read more about the company. Good luck in the am and happy trading!!



TEL AVIV, Israel, July 30, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today announced a strategy of targeting new international market opportunities. In particular, the company has identified the emerging markets of Russia and Commonwealth of Independent States (CIS)



Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. The health market opportunity is estimated at over $10 billion and forecast to grow at an impressive five-year compound average growth rate (CAGR) of 18.1% in US dollar terms.



According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.



mBeach CEO Yossi Biderman commented, "One of the main reasons for relatively high cancer death rates in Russia and CIS is that patients are often diagnosed with the disease once it is too late. This is a very large and growing healthcare market and represents an important opportunity for Skin Cancer Scanning (SCS), our wholly owned subsidiary company. Our simple-to-use, non-invasive, point-of-care, skin cancer detection solution is ideally suited for this market."



About SCS



Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.



Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.



For more information on SCS, visit Skin Cancer Scanning Ltd. (SCS) :: Symbol (OTCBB): MBHS.

[PENNYMASTER]

More news..

mBeach Software Inc. Signs a Memorandum of Understanding in Emerging Russian and CIS Markets

TEL AVIV, Israel, Aug 2, 2010 (GlobeNewswire via COMTEX) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today announced the signing of a memorandum of understanding (MOU) for the future distribution of SkinScan 650, the medical device for detection and diagnosis of skin cancer, signed by the wholly owned subsidiary, Skin Cancer Scanning Ltd. with a Russian Corp, active in the medical device field. This follows the company's recent announcement that it is targeting new market opportunities in this emerging region.
The new MOU covers the regulatory certification required by the Russian regulator, regional sales, marketing and distribution of SkinScan 650, SCS's non-invasive, point-of-care system to detect and identify different types of skin cancers.

Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.

"This MOU is an important element of our growth strategy for this region," said mBeach CEO Yossi Biderman. "Our product, though still a prototype, will be ideally suited, once the industrial prototype is approved by the Russian regulator, to meet the growing demand for better cancer detection. We are very excited at the potential of this market and see this MOU as a stepping stone to entering additional, attractive markets around the world."

We could see a big open on this one is the am. This could be the time to take a position in this one. It has the indications of showing some awesome gains. Early detection of caner is the only true way of beating it. Foreign investors should be looking at this one now its being marketed in Russia!!

[PENNYMASTER]

News after the bell today. Company has been quiet lately. Looks like its coming back into play with some good news and an update on what the company is currently doing and how they are protecting our investments in the international market. Here is the complete news...



mBeach Software Inc. Targets New International Markets: Extends Global Patent Protection

TEL AVIV, Israel, Aug 18, 2010 (GlobeNewswire via COMTEX) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today announced the filing of additional patent applications under the framework of the Patent Cooperation Treaty (PCT). This move will facilitate the company's strategy to enter new international markets for its advanced, non-invasive system to detect and identify skin cancer.

Skin Cancer Scanning Ltd. ("SCS"), the wholly owned subsidiary, has already submitted a patent application in the United States (application number 11/464,838) with a priority date of August 2006. The patent office is currently examining this application and the company expects the patent to be approved and published by the end of 2010.

In addition to the United States, SCS has filed patent applications in many important markets around the world. These countries include Canada, Japan, Australia, China, South Korea, Singapore, New Zealand, Israel, South Africa, Brazil, Mexico, Russia and the Commonwealth of Independent States (CIS), Ukraine, and the European Union. These patent applications have now reached the national phase of registration.

"Our intellectual property is one of the company's most valuable assets," said mBeach CEO Yossi Biderman. "We are taking all necessary measures to protect this asset, including patent applications and other appropriate actions. International growth is an important part of our strategy for growth. We want to make sure we have the right patent protection in all our major potential markets as soon as possible."

[PENNYMASTER]

TEL AVIV, Israel, Aug. 20, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update on the growing market for skin cancer diagnostic solutions. These market developments represent significant opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.

We have identified the Japanese, Hi-Tech orientated market, as a potential pivotal market, with increasing awareness to skin cancer related issues in the past decade.

Total population of Japan exceeds 125 million people, and there is increasing demand for advanced medical technologies.

The number of patients with malignant skin tumors has increased year by year.

The annual increase of deaths from Non Melanoma Skin Cancer (NMSC) is 3.8%. (Hisashi Ohtsukaa, Shogo Nagamatsub).

Early detection is critical to survival, and can lead to almost a one hundred percent cure rate. However, the effectiveness of current cancer detection procedures is heavily dependent on the experience of the examiner, and errors in diagnosis can be fatal. Occasionally, cancers remained undetected, grow further and lead to lower chances of survival. An additional disadvantage with current diagnostic methods is that they rely on a biopsy, the intrusive removal of tissue sample, to confirm the presence of cancerous tissue.

Biopsies can be painful, leave scarring, and often cause unnecessary patient anxiety.

SCS is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.

mBeach CEO Yossi Biderman commented," The Japanese market and other intended market surveys are being initiated at these early stages due to the lengthy regulatory procedures in each country, before receiving marketing approval. We expect initial approvals to coincide with industrial device following clinical trials, during 2011".

[PENNYMASTER]

Not too bad of a day here on MBHS, Company had news at the close and it explains a little about there marketing strategy. Charts look good on this one. We have .24 as a support and a slight resistance at .30 which could be broken. This one could easily run. Keep you eyes peeled.



mBeach Software Inc. Defining Marketing Strategy for Non-Intrusive Technologies for the Detection of Skin Cancer

TEL AVIV, Israel, Aug 23, 2010 (GlobeNewswire via COMTEX) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today issued a stockholder update on its Evolving Marketing Strategy for skin cancer diagnostic solutions. The adopted strategy represents an entrepreneurial concept approach to locating and initiating opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.

The initially targeted countries are the USA, Russia and the CIS, Australia, Germany, Japan, and Israel.

The Basic Strategy concept is a four pillar structure: Preliminary logistics for initiation and maintenance of service for large volume of demand for the device; Advanced survey to define all relevant aspects (Production, Distribution, Tech Support); Survey of the specific targeted regions; Locate and engage a distributor, meeting with the requirements, in the defined country/state/ region.

The marketing strategy in every country will be basically similar and will be executed in similar initial stages. The differences will be the result of health reimbursement programs, Medicare concept, and conduct of distribution and use of medical devices.

mBeach is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.

mBeach CEO Yossi Biderman commented, "The marketing strategy we have defined at this early stage is due to the lengthy regulatory procedures in each country. We expect that the mutual impact of market demand and technical innovative approach on the final product will result in what we think will be a most advanced, adaptable, and technically supported, medical device for the early detection of skin cancer. We expect our SkinScan 650, a non-invasive, point-of-care, doctors' decision supporting device, to provide the Medical practitioner a much needed user friendly diagnostic solution."